Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

NCT02748304 · clinicaltrials.gov ↗
NA
Phase
TERMINATED
Status
52
Enrollment
OTHER
Sponsor class

Stopped The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.

Conditions

Interventions

Sponsor

Fudan University